Update following Attana’s participation at the Drug Discovery V-Forum
On April 21, Attana participated in the conference Drug Discovery V-Forum to present the company and listen in to presentations from other companies within the Life Science industry.
This marked yet another conference where Attana had the opportunity to communicate its products and services to potential customers and partners. The company also presented preliminary results from the ongoing work with Attana Diagnostics and the development of a SARS-CoV-2 immunoassay.
Attana’s recorded presentation can be found here.
For more information, please contact:
Teodor Aastrup, CEO
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact email@example.com